Pulmatrix (NASDAQ:PULM) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Pulmatrix (NASDAQ:PULM) in a research note issued to investors on Monday. The firm set a “hold” rating on the biotechnology company’s stock.

Pulmatrix Price Performance

PULM opened at $6.56 on Monday. Pulmatrix has a 1-year low of $1.55 and a 1-year high of $7.87. The firm has a market cap of $23.96 million, a P/E ratio of -2.48 and a beta of 0.99. The company has a 50 day simple moving average of $2.25 and a two-hundred day simple moving average of $2.10.

About Pulmatrix

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.